Prevalence and incidence of diabetes in Norway

1983 ◽  
Vol 104 (4_Suppl) ◽  
pp. S19-S20
Author(s):  
Kristian Midthjell
Keyword(s):  
Type 2 Diabetes ◽  
Diabetes Type 2 ◽  
Limited Data ◽  
Prevalence Data ◽  
Age Related ◽  
Type 2 Diabetes Treatment ◽  
Definition Of ◽  
Hospital Outpatients

ABSTRACT. There are limited data on the prevalence of Type 2 diabetes in Norway, since most studies conducted have not tried to separate between Type 1 and Type 2 diabetes. The prevalence of known diabetes in patients over 14 years was reported as 0.7 % in 1956. The present prevalence of known diabetes probably is about twice this percentage. This will be estimated in a planned study. The treatment behaviour of Norwegian physicians has been analysed in a preliminary study. Based on this, 90 % of the patients at hospital outpatients clinics used insulin compared with only 16 % in general practice. The criteria applied for definition of diabetes varied considerably among the physicians, only 50 % of them using the WHO criteria. Age related prevalence data will be determined in a future screening project. Key words: prevalence, incidence, Type 1 diabetes, Type 2 diabetes, treatment, Norway.

scholarly journals Type 2 Diabetes Mellitus (T2DM) may have Four Subtypes Beneficial for Adequate Treatment

2021 ◽  
Vol 4 (1) ◽  
pp. 38-41
Author(s):  
Bando H
Keyword(s):  
Type 2 Diabetes ◽  
Diabetes Type 2 ◽  
Adequate Treatment ◽  
Insulin Resistant ◽  
Age Related ◽  
Cluster A ◽  
Diabetic Treatment ◽  
Mild Obesity

Diabetes includes various heterogeneous factors. Similar to subtypes of type 1 diabetes, type 2 diabetes may show four subtype clusters. They are cluster A: severe insulin-deficient diabetes, B: severe insulin-resistant diabetes, C: mild obesity-related diabetes, and D: mild age-related diabetes. Comparing them, the prevalence of nephropathy and cardiovascular events was highest in the cluster A. Reference data are i) the ratio of cluster A-D is 18.7%, 23.7%, 21.1%, 36.4%, ii) HbA1c for A-D is 11.05%, 8.17%, 8.49%, 7.95%, iii) event ratio of MACE is 14.4%, 10.6%, 11.4%, 9.1%. Future diabetic treatment is hopefully provided suitable for each subtype.

scholarly journals Increased Tau Phosphorylation and Cleavage in Mouse Models of Type 1 and Type 2 Diabetes

Endocrinology ◽  
2009 ◽  
Vol 150 (12) ◽  
pp. 5294-5301 ◽  
Author(s):  
Bhumsoo Kim ◽  
Carey Backus ◽  
SangSu Oh ◽  
John M. Hayes ◽  
Eva L. Feldman
Keyword(s):  
Type 2 Diabetes ◽  
Mouse Models ◽  
The United States ◽  
Tau Phosphorylation ◽  
Age Related ◽  
Increased Risk ◽  
And Gender ◽  
Tau Cleavage

Abstract As the population of the United States ages, the incidence of age-related neurodegenerative and systemic diseases including Alzheimer’s disease (AD) and diabetes is increasing rapidly. Multiple studies report that patients with diabetes have a 50–75% increased risk of developing AD compared with age- and gender-matched patients without diabetes. Abnormally phosphorylated tau is a major building block of neurofibrillary tangles, a classic neuropathological characteristic of AD. In addition, proteolytic tau cleavage promotes AD progression due to cleaved tau serving as a nucleation center for the pathological assembly of tau filaments. The current study examines tau modification in type 1 (streptozotocin-injected) and type 2 (db/db) mouse models of diabetes. Tau phosphorylation is increased in the cortex and hippocampus of db/db mice compared with db+ control mouse brain. Interestingly, there is an age-dependent increase in tau cleavage that is not observed in age-matched control db+ animals. Streptozotocin injection also increased tau phosphorylation; however, the increase was less significant compared with the type 2 mouse model, and more importantly, no tau cleavage was detected. Our results suggest tau modification caused by insulin dysfunction and hyperglycemia may contribute to the increased incidence of AD in diabetes. We hypothesize that type 1 and type 2 diabetes may contribute to AD through different mechanisms; in type 2 diabetes, hyperglycemia-mediated tau cleavage may be the key feature, whereas insulin deficiency may be the major contributing factor in type 1 diabetes.

scholarly journals Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019

2021 ◽  
Vol 12 ◽  
Author(s):  
Yujiao Deng ◽  
Na Li ◽  
Ying Wu ◽  
Meng Wang ◽  
Si Yang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Type 1 Diabetes ◽  
Kidney Disease ◽  
Public Health Problem ◽  
Diabetes Type 2 ◽  
Life Years ◽  
Incident Cases

BackgroundChronic kidney disease (CKD) is a public health problem largely caused by diabetes. The epidemiology of diabetes mellitus–related CKD (CKD-DM) could provide specific support to lessen global, regional, and national CKD burden.MethodsData were derived from the GBD 2019 study, including four measures and age-standardized rates (ASRs). Estimated annual percentage changes and 95% CIs were calculated to evaluate the variation trend of ASRs.ResultsDiabetes caused the majority of new cases and patients with CKD in all regions. All ASRs for type 2 diabetes–related CKD increased over 30 years. Asia and Middle socio-demographic index (SDI) quintile always carried the heaviest burden of CKD-DM. Diabetes type 2 became the second leading cause of CKD and CKD-related death and the third leading cause of CKD-related DALYs in 2019. Type 2 diabetes–related CKD accounted for most of the CKD-DM disease burden. There were 2.62 million incident cases, 134.58 million patients, 405.99 thousand deaths, and 13.09 million disability-adjusted life-years (DALYs) of CKD-DM worldwide in 2019. Age-standardized incidence (ASIR) and prevalence rate (ASPR) of type 1 diabetes–related CKD increased, whereas age-standardized death rate (ASDR) and DALY rate decreased for females and increased for males. In high SDI quintile, ASIR and ASPR of type 1 diabetes–related CKD remained the highest, with the slowest increase, whereas the ASDR and age-standardized DALY rate remained the lowest there. In high SDI quintile, ASIR of type 2 diabetes–related CKD was the highest, with the lowest increasing rate. In addition, type 2 diabetes–related CKD occurred most in people aged 80-plus years worldwide. The main age of type 2 diabetes–related CKD patients was 55–64 years in Asia and Africa. The prevalence, mortality, and DALY rate of type 2 diabetes–related CKD increased with age. As for incidence, there was a peak at 80 years, and after age of 80, the incidence declined. CKD-DM-related anemia was mainly in mild to moderate grade.ConclusionsIncreasing burden of CKD-DM varied among regions and countries. Prevention and treatment measures should be strengthened according to CKD-DM epidemiology, especially in middle SDI quintile and Asia.

Sign in / Sign up

Export Citation Format

Share Document